

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Brown, et al.

International App. No.:

PCT/US03/022716

Group Art Unit:

International Filing Date: July 21, 2003

Examiner:

For:

PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS

**Commissioner for Patents** Washington, D.C. 20231


## INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

		and continuity made of resolution in the provisions of the continuity						
	<ul> <li>[ ] Copies of the references are enclosed</li> <li>[ ] Copies of the references were submitted in parent application Serial No (37 CFR 1.98 [X] A copy of the International Search Report which issued on International Application No. PCT/US03/022716 is submitted herewith. All of the publications cited in the International Search Rep are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to U.S. Patent Office by the International Bureau.</li> </ul>							
A.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).						
	OR []	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).						
В.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  (1) a final action under § 1.113 or  (2) a notice of allowance under § 1.311, nichever occurs first.						
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.						
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).						

Express Mail Label EV332065482US





C. [] The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [] A duplicate copy of this paper is attached.

Respectfully Submitted,

John L. Lemanowicz Attorney for Appliant

Registration No. 37,380

Date: 20 dan 2005

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8247 Facsimile: (919) 483-7988

DT01 Rec'd PCT/PT 2 0 JAN 2005

FORM PT		49 N DISCLOSURE	E STATEMENT	Г	ATTORNEY DOCK NO. PU4687USW		INTERNATIONAL 5 (APP. NO) 22 U 5 (PCT/US03/022716		
					APPLICANT				
					Brown et al.  INTERNATIONAL GROUP				
					FILING DATE 7/21/03		GROUP		
Examiner	l Fatent i		Issue Date			Class	Subclass	Filing Date If Appropriate	
Initials		Number	<u> </u>	Dow et al.					
	1	5,593,997	1/14/97						
	ļ			ļ					
				<u></u>				<u>J </u>	
				ntinue on					
	1	T 5 '	1	N PATEN	T DOCUMENT	<u>S</u>		Translation	
		Document	Publication Date		Country	Class	Subclass	Yes   No	
	2	Number 00/38675	7/6/00	PCT	Country	Class	Subclass	<del> </del> -	
	3	01/19829	3/22/01	PCT				<u></u>	
	4	98/14449	4/9/98	PCT				<del> </del>	
	+-	70/1447	4/3/30	101					
	1			<u> </u>					
, t t	1		Co	ontinue on	page		<u></u>	<u> </u>	
	O'	THER DOCUME				Date, Page Nu	mber, Etc.)		
	<del>                                     </del>		<del></del>						
				_					
		<del></del>			<del></del>				
	<del> </del>	-							
	+-								
		<del>                                     </del>							
· <del>-</del> -	+-	<del> </del>							
	.1		C	ontinue on	nage				
EXAMINER Continue on page _						DATE CONSIDERED			
	J41								
EXAMINE	R: In	itial if citation co	nsidered, wheth	er or not c	itation is in confo	ormance with I	MPEP § 609: E	Praw line	

applicant.